ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2008
Inflamed phenotype of the mesenteric microcirculation of melanocortin type 3 receptor-null mice after ischemia-reperfusion.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- Resolution Pharmacology: State-of-the-art and therapeutic landscape.Pharmacological reviews · 2025Review
- Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases.Diseases (Basel, Switzerland) · 2025Review
- The Resolution Approach to Cystic Fibrosis Inflammation.Frontiers in pharmacology · 2020Review
- Melanocortin Regulation of Inflammation.Frontiers in endocrinology · 2019Review
- Underlying chronic inflammation alters the profile and mechanisms of acute neutrophil recruitment.The Journal of pathology · 2016Article
- Both MC1 and MC3 Receptors Provide Protection From Cerebral Ischemia-Reperfusion-Induced Neutrophil Recruitment.Arteriosclerosis, thrombosis, and vascular biology · 2015Article
- Melanocortin peptides: potential targets in systemic lupus erythematosus.Inflammation · 2015Review
- Melanocortin receptor accessory proteins in adrenal disease and obesity.Frontiers in neuroscience · 2015Review
- Annexin A1 mediates hydrogen sulfide properties in the control of inflammation.The Journal of pharmacology and experimental therapeutics · 2014Article
- Association between periodontal disease and inflammatory arthritis reveals modulatory functions by melanocortin receptor type 3.The American journal of pathology · 2014Article
- Article
- Control of myeloid cell trafficking in resolution.Journal of innate immunity · 2013Review
- Chondroprotective and anti-inflammatory role of melanocortin peptides in TNF-α activated human C-20/A4 chondrocytes.British journal of pharmacology · 2012Article
- The melanocortin agonist AP214 exerts anti-inflammatory and proresolving properties.The American journal of pathology · 2011Article
- Physiological roles of the melanocortin MC₃ receptor.European journal of pharmacology · 2011Review
- Article
- Role of melanocortin receptors in the regulation of gouty inflammation.Current rheumatology reports · 2011Review
- The melanocortin 3 receptor: a novel mediator of exercise-induced inflammation reduction in postmenopausal women?Journal of aging research · 2011Article
- Melanocortin receptors as novel effectors of macrophage responses in inflammation.Frontiers in immunology · 2011Article
- The melanocortin MC(1) receptor agonist BMS-470539 inhibits leucocyte trafficking in the inflamed vasculature.British journal of pharmacology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
The existence of anti-inflammatory circuits centered on melanocortin receptors (MCRs) has been supported by the inhibitory properties displayed by melanocortin peptides in models of inflammation and tissue injury. Here we addressed the pathophysiological effect that one MCR, MCR type 3 (MC3R), might have on vascular inflammation. After occlusion (35 min) and reopening of the superior mesenteric artery, MC3R-null mice displayed a higher degree of plasma extravasation (45 min postreperfusion) and cell adhesion and emigration (90 min postreperfusion). These cellular alterations were complemented by higher expression of mesenteric tissue CCL2 and CXCL1 (mRNA and protein) and myeloperoxydase, as compared with wild-type animals. MC1R and MC3R mRNA and protein were both expressed in the inflamed mesenteric tissue; however, no changes in vascular responses were observed in a mouse colony bearing an inactive MC1R. Pharmacological treatment of animals with a selective MC3R agonist ([D-Trp(8)]-gamma-melanocyte-stimulating hormone; 10 microg i.v.) produced marked attenuation of cell adhesion, emigration, and chemokine generation; such effects were absent in MC3R-null mice. These new data reveal the existence of a tonic inhibitory signal provided by MC3R in the mesenteric microcirculation of the mouse, acting to down-regulate cell trafficking and local mediator generation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.